Literature DB >> 10503570

Sexual activity and the cardiovascular patient: guidelines.

H A Taylor1.   

Abstract

Modern cardiac rehabilitation is a comprehensive program of secondary prevention for patients with heart disease. Moreover, it is an important context in which to broach issues of impaired sexual function. Sexual problems plague a large portion of our cardiac patient population. Unspoken+ concerns about impotence, now more correctly called erectile dysfunction (ED), are common, as are concerns about the safety of engaging in sexual activity, especially after major cardiac events or therapeutic interventions. A large proportion of patients do not return to normal sexual activity after a cardiac event. Many factors, including normal age-related changes in sexual response, medication-induced dysfunction, and vascular changes associated with risk factors (e.g., diabetes and dyslipidemia), as well as the emotional impact of symptomatic heart disease, may influence sexual function in these patients. These factors, occurring alone or in combination, probably explain the discouraging prevalence of sexual dysfunction in patients with manifest cardiac disease. Because so few patients have specific cardiac reasons for limiting sexual activity, a clear opportunity exists for cardiologists and their staff to help enhance the emotional well-being and overall quality of life of their cardiac patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503570     DOI: 10.1016/s0002-9149(99)00116-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  General practitioner views about discussing sexual issues with patients with coronary heart disease: a national survey in Ireland.

Authors:  Molly Byrne; Sally Doherty; Hannah M McGee; Andrew W Murphy
Journal:  BMC Fam Pract       Date:  2010-05-25       Impact factor: 2.497

2.  Discussing sexual function in the cardiology practice.

Authors:  M P J Nicolai; S Both; S S Liem; R C M Pelger; H Putter; M J Schalij; H W Elzevier
Journal:  Clin Res Cardiol       Date:  2013-02-08       Impact factor: 5.460

Review 3.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.